Efficacy and side effects of Fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki is a antibody-drug conjugate (ADC) that targets HER2 cancers. It has two parts, a humanized anti-HER-2 monoclonal antibody and the topoisomerase inhibitor payload deruxtecan, which has shown promising objective response rates in a variety of cancers, namely non-small cell lung cancer that expresses the HER2 protein, HER2-positive breast cancer, which cannot pass After surgical resection, or after treatment for anti-HER2 breast cancer that has metastasized to other organs in the body, or metastasis or disease recurrence occurs throughout the course of treatment or within 6 months of completing treatment; and HER2+ advanced gastric cancer, the identified adverse reactions observed in patients were nausea, decreased appetite, vomiting, musculoskeletal pain, fatigue, diarrhea, alopecia, and constipation.